Our First-in-Class Platform to Quantify Tumor Adaptation
Most drug discovery measures early response. Cancer adapts.
Resistance is driven by dynamic phenotypic plasticity, which is the ability of cancer cells to reconfigure under stress. It often goes undetected. Cymoplive is a state-of-the-art platform designed to measure dynamic tumor behavior beyond initial drug response.
Our technology enables time-resolved assessment of these adaptive processes, delivering actionable insights into early adaptive responses, emerging resistance, and drug durability to strengthen translational decision-making in oncology development.
Cymoplive for Society
Reducing Animal Dependency
An estimated 50–100 million animals are used globally in research each year. Cymoplive advances human-relevant models aligned with regulatory support for New Approach Methodologies (NAMs) that promote Replacement, Reduction, and Refinement. By leveraging human biology-based systems, we reduce reliance on animal studies while improving translational relevance.
Improving Predictive Power
Most oncology therapies fail due to limited human predictivity. Cymoplive captures adaptive cancer behaviour earlier, enabling better anticipation of resistance and improving confidence in human outcomes.
Accelerating Development
Traditional preclinical workflows are slow and iterative. Cymoplive provides earlier insight into resistance dynamics, reducing time spent advancing non-viable candidates and supporting faster, data-driven decisions.
Advancing Sustainable Research
We promote a circular research approach by reusing biological byproducts and minimising experimental waste, supporting more ethical and resource-efficient innovation.